Poly(ADP-ribose) polymerases, commonly referred to as PARPs, encompass a family of enzymes critical for DNA damage response (DDR), chromatin structure maintenance, and transcriptional regulation. These enzymes utilize NAD⁺ as a substrate for ADP-ribosylation modifications. The human PARP family consists of numerous members, each possessing both conserved catalytic domains and unique regulatory domains, which contribute to their diverse biological roles. Among these, PARP1 and PARP2 are particularly noteworthy due to their involvement in DNA repair processes.

Cancer Treatment Potential

Inhibiting PARP1 and PARP2 can disrupt mechanisms responsible for repairing single-strand breaks in DNA, leading to synthetic lethality in BRCA-deficient tumors, among other cancer types. The development of PARP inhibitors has emerged as a groundbreaking therapeutic approach for treating various malignancies, notably those with defective homologous recombination. Beyond PARP1 and PARP2, novel therapeutic targets within the PARP family, such as tankyrases, have been identified, expanding the potential for targeted cancer therapies.

Our Comprehensive Screening Services

Creative Bioarray specializes in providing state-of-the-art in vitro PARP screening services designed to evaluate the inhibitory potential of diverse compounds efficiently. Our high-throughput screening platform allows researchers to rapidly assess both the catalytic inhibition and target engagement of compounds, essential for predicting their in vivo activity and potential toxicology.

Key Features of Our Screening Services

• Biochemical Catalytic Inhibition Assessment: Utilizing recombinant PARP enzymes, this assay measures the extent to which inhibitors block NAD⁺ consumption and ADP-ribose transfer.
• PARP-DNA Trapping Evaluation: By employing fluorescently labeled DNA duplexes, this test identifies compounds that promote PARP trapping on DNA, indicated by increased fluorescence polarization signals.

Service Highlights

• Rapid and Efficient Screening: Our automated platforms enable the swift examination of large compound libraries, dramatically cutting down screening timelines.
• Dependable and Accurate Data: We adhere to stringent industry standards, ensuring that all data generated is reliable, reproducible, and documented in comprehensive reports.
• Customizable Options: Our assays can be tailored to fit specific project needs, accommodating various PARP subtypes and concentration ranges.
• Expert Support: Our team is available to provide guidance and customize services according to your particular requirements, enhancing the overall research experience.

Conclusion

Creative Bioarray is committed to advancing your drug discovery efforts through our robust PARP screening services. We invite you to contact us to explore how our solutions can facilitate your research objectives and contribute to the development of effective therapeutic agents against cancers driven by PARP dynamics.